A chronic disappointment for Viridian
Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.
Biopharma buyouts bounce back
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Big biotech's upcoming clinical priorities
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
UCB leads the stale scale
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
ADA 2023 – Lilly unveils its triple threat
Retatrutide looks like the most powerful obesity agent yet, though side effects will need careful monitoring.
More details needed on Sanofi’s atopic dermatitis win
The anti-Ox40 ligand antibody amlitelimab could have its work cut out to best the company’s own Dupixent.
Lilly signs up Verve to take on Novartis and Amgen
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.